



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/806,288	03/23/2004	Bengt Guss	GUSS3001D/JDB	1848

23364 7590 10/15/2004

BACON & THOMAS, PLLC
625 SLATERS LANE
FOURTH FLOOR
ALEXANDRIA, VA 22314

EXAMINER

DEVI, SARVAMANGALA J N

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 10/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO. /CONTROL NO. 10/806,288	FILING DATE 3/23/2004	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION Guss et al.	ATTORNEY DOCKET NO. GUSS3001D/JDB
--	--------------------------	---	--------------------------------------

EXAMINER

S. Devi, Ph.D.

ART UNIT	PAPER
1645	102004

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

The instant specification recites nucleic acid and/or amino acid sequences that contain more than ten bases and/or four amino acid residues, yet does not identify the sequences by sequence identifiers or SEQ ID numbers as required. For example, the section 'Sequence list' on pages 19-21 of the specification represents a nucleotide sequence and an amino acid sequence, as indicated at the bottom of page 21 of the specification. Yet the amendment to this section of the specification filed 04/30/04 does not identify both the sequences with specific SEQ ID numbers, as required under 37 C.F.R. 1.821 through 1.825. Similarly, Figures 6A-6E, as amended, represent a nucleotide sequence and an amino acid sequence as indicated via the amended specification beginning at line 2 of page 2. Yet the amendment to this section of the specification filed 04/30/04 does not identify both the sequences with specific SEQ ID numbers, as required under 37 C.F.R. 1.821 through 1.825. Every amino acid sequence recited in the specification that is longer than four amino acids and every nucleotide sequence recited in the specification that is longer than ten nucleotide bases *must* be identified by a SEQ ID number as required under 37 C.F.R. 1.821 through 1.825. If not included already, such SEQ ID numbers should be included in the raw Sequence Listing.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>>, EFS Submission User Manual - ePAVE)

2. Mailed to:

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner S. Devi, Ph.D., whose telephone number is (571) 272-0854.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith can be contacted at (571-272-0864).

CD. Oct 2006.04
S. DEVI, PH.D.
PRIMARY EXAMINER

HOW TO SEND SEUQUENCES TO USPTO

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebc/efs/downloads/documents.htm>),
EFS Submission User Manual - ePAVE)
2. Mailed to:
Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313-1450
Alexandria, VA 22313-1450
3. Hand Carried directly to the Customer Window at:
U. S. Patent and Trademark Office
Box Sequence, Customer Window, Lobby, Room 1B03
Crystal Plaza Two
2011 South Clark Place
Arlington, Virginia 22202
4. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
Box Sequence, Room 1B03-Mailroom
Crystal Plaza Two
2011 South Clark Place
Arlington, Virginia 22202